Business
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\nbiOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain \n\nbiOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain\n\n\n VANCOUVER, BC--(Marketwired - March 17, 2016) -  biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the \"Company\") on Saturday, March 19, 2016 at 11:45am, will present the data from the biOasis sponsored Brains for Brain (\"B4B\") lysosomal storage disease (\"LSD\") knockout mouse study performed by Dr. Maurizio Scarpa and Dr. Rosella Tomanin at Dr. Scarpa's laboratories in Padova, Italy. Dr. Scarpa is a world leading clinical expert in lysosomal storage diseases. The study, which was started in late 2014, was focused on Hunter Syndrome, or mucopolysaccharidosis II (MPS II), a serious genetic disorder that primarily affects males. Symptoms of the disease are usually evident in children between the ages of 2 to 4 years. With Hunter Syndrome, there is a build-up of glycosaminoglycans (\"GAGs\") in cells throughout the body due to the absence or improper functioning of an enzyme, iduronate-2-sulfatase (\"I2S\"). The buildup of GAG interferes with the way certain cells and organs in the body function and leads to a number of serious symptoms, some of which are significantly evident in the brain. The treatment for Hunter Syndrome is enzyme replacement therapy (\"ERT\"), the administration of the I2S enzyme. However, I2S cannot normally cross the blood-brain barrier, leaving the brain untreated.The mouse model used in the B4B study, developed by Dr. Scarpa, was bred with the inability to produce the I2S enzyme. The study was key to determining whether biOasis Transcendpep could deliver IS2 to the brain and could clear or decrease the number of lysosomal storage vacuoles from the cells within the brain, a key measurement in the successful treatment of Hunter Syndrome within the brain. The study showed that the Transcendpep fusion protein, MTfp-I2S (MTfp-Iduronate-2-sulfatase), crossed the blood-brain barrier, reached therapeutic levels in the CNS and significantly decreased the number of lysosomal storage vacuoles in the cytoplasm of brain cells.\"biOasis has seen some wonderful advancements within its internal programs and although this study was longer than expected, the results wer...